

INVESTMENT HIGHLIGHTS

- BioCorRx has reported a 12% increase in revenues in Q2-2017.
- The recovery program is being implemented in several clinics in the US.
- BioCorRx has partnered with the Virtual Reality Medical Center.
- The company has been attending numerous conferences in the US to market its services.

OVERVIEW

BioCorRx, Inc. (BICX) distributes and licenses the BioCorRx® Recovery Program for alcoholism and opioid addiction treatment. The company offers a unique treatment strategy that combines medical intervention with a counseling and coaching program. The company is also developing unique ways to deliver Naltrexone to patients through its research and development subsidiary BioCorRx Pharmaceuticals. The company is also focused on new innovative ways to treat addiction, evidenced by their recent collaboration with DynamiCare to develop mobile applications for patients with opioid and alcohol addiction.

COMPANY DATA

52-Week Range (\$)	0.01-0.34
Shares Outstanding (mn)	242.1
Market Cap (\$ mn)	20.15
3-Mo. Average Volume (mn)	540.69
12-Mo. Price Target (\$)	n/a
Total Cash (\$ mn)	0.85
Total Debt (\$ mn)	1.45
Dividend Yield (%)	0
Short Interest (%)	n/a
Insider Ownership (%)	22.18
Institutional Ownership (%)	n/a
Top 6 Holders (%)	22.18

KEY FINANCIALS (in \$ millions, except EPS)

	FY13A	FY14A	FY15A	FY16A
Revenue	0.715	1.171	0.925	0.702
EPS	(0.03)	(0.02)	(0.03)	(0.03)
Net Income	(3.839)	(3.128)	(4.666)	(5.904)
EBIT	(2.5)	(3.053)	(1.478)	(2.049)
EBITDA	(2.365)	(2.917)	(1.353)	(2.019)

SHARE PRICE PERFORMANCE



Q2-2017 RESULTS

The company has recently released the second quarterly result for the three months ended June 30, 2017 where it has reported a 12% increase in revenue. Sales were \$210,544, compared to \$187,912, for the three months ended June 30, 2016. This growth is directly related to the increased number of patients treated at licensed clinics and an increase in BioCorRx® Recovery Program distribution.

On the other hand, it is worth mentioning that, considering the past six months, the revenue has actually decreased by 17.6%, as displayed below. However, as the recovery program is being implemented in several facilities in the US, a more reliable revenue growth is expected for the next quarters.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD (\$)	3 Months Ended		6 Months Ended	
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Consolidated Statements of Operations				
Revenues, net	\$ 210,544	\$ 187,912	\$ 344,771	\$ 418,325
Operating expenses:				
Cost of implants and other costs	166,665	46,185	190,015	86,638
Research and development	43,339	0	51,570	0
Selling, general and administrative	778,693	553,224	1,285,293	944,463
Termination of licensing agreement				132,804
Depreciation and amortization	8,465	795	16,854	1,368
Total operating expenses	997,162	600,204	1,543,732	1,165,273
Loss from operations	(786,618)	(412,292)	(1,198,961)	(746,948)
Other income (expenses):				
Gain on settlement of debt	285,924		285,924	
Interest expense, net	(459,064)	(223,127)	(10,220,569)	(388,359)
Gain (loss) on change in fair value of derivative liability	12,263,680	(438,344)	(15,897,993)	(467,041)
Total other income (expenses)	12,090,540	(661,471)	(25,832,638)	(855,400)
Income (loss) before income taxes	11,303,922	(1,073,763)	(27,031,599)	(1,602,348)
Income taxes				
Net Income (loss)	\$ 11,303,922	\$ (1,073,763)	\$ (27,031,599)	\$ (1,602,348)
Net income (loss) per common share, basic	\$ 0.05	\$ (0.01)	\$ (0.12)	\$ (0.01)
Net income (loss) per common share, diluted	\$ 0.02	\$ (0.01)	\$ (0.12)	\$ (0.01)
Weighted average number of common shares outstanding, basic	241,730,516	165,394,501	222,279,257	165,166,479
Weighted average number of common shares outstanding, diluted	579,668,702	165,394,501	222,279,257	165,166,479

Source: BioCorRx 10-Q, 2017

BioCorRx® RECOVERY PROGRAM DEVELOPMENT

BioCorRx announced in July that it had entered into an agreement with centers in three different states that will be implementing the BioCorRx® Recovery Program. The program is a non-addictive, medication-assisted treatment (MAT) plan that combines a Naltrexone implant with a proprietary counseling program and peer support specifically tailored for the treatment of alcoholism and opioid use disorder.

The centers in agreement with BioCorRx are:

- Hope Recovery and Wellness in West Palm Beach in West Palm Beach, Florida.
- EnLite Clinics in Ohio (at three locations), which is considered by many to be the epicenter of the opioid crisis.
- Serrano Kidney and Vascular Access Center of California in Los Angeles, California.

VIRTUAL REALITY MEDICAL CENTER PARTNERSHIP

BioCorRx partnered in June 2017 with the Virtual Reality Medical Center (VRMC), led by Drs. Mark and Brenda Wiederhold, as well as Dr. Joseph Shurman, co-director of the Pain and Palliative Care Committee at Scripps Memorial Hospital in La Jolla, California, to conduct a study on the BioCorRx® Recovery Program and the company's long-lasting Naltrexone implant.

With this partnership, the company will gain more third-party support for its recovery program and will bring synergy to its plan of seeking FDA approval for its implant.

CONFERENCES ATTENDANCE

In order to increase brand awareness, BioCorRx has attended several conferences in the past few months:

- On June 15th, the company presented at the Marcum MicroCap Conference and met with potential investors.
- From July 27th to 29th, the company had an exhibit in the American Society of Addiction Medicine (ASAM) Review Course in Addiction Medicine in Dallas, Texas. The conference is recognized as the essential primer for physicians and other healthcare professionals who are preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.
- From August 24th to 27th, the company had an exhibit in the California American Society of Addiction Medicine (ASAM) Review Course in Addiction Medicine in San Francisco, California.

On top of that, the company's management also appeared as guests on Fox 11 Morning News Los Angeles on June 8th to discuss the BioCorRx® Recovery Program, which is being offered to Anaheim residents suffering from alcohol and opioid addiction as part of the Drug Free Anaheim initiative.

COMPANY DESCRIPTION

BioCorRx, Inc. (OTC: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consisting of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, Naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term Naltrexone treatment. The company also has a R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable Naltrexone technology (BICX 101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX 101.

COMPANY INFORMATION

research@jgrcap.com
646.688.3131

DISCLOSURE

This report has been prepared and distributed by JGR Capital Partners, LLC and constitutes paid company-sponsored research. This report is based on sources that we consider reliable, including the subject of the report, but not any material non-public information. We do not represent that this report is accurate or complete, and it should not be relied on as such. All information contained herein is subject to change without notice.

This report is not disseminated in connection with any distribution of securities and is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual persons. Recipients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Statements included in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues.

JGR Capital Partners, LLC has been compensated for the preparation of this report and has been retained for one year by BioCorRx, Inc. (BICX) via cash payment of three thousand five hundred dollars and one hundred thousand shares of company restricted stock to provide paid company sponsored research. The purpose of the fee is to subsidize the high costs of research and monitoring. JGR Capital Partners, LLC is not a broker-dealer and does not generate any investment banking or commission-based revenue with respect to the securities of the company described herein. Our professionals may provide oral or written market commentary that reflects opinions that are contrary to the opinions expressed in this report. The price and value of the shares referenced in this report may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors.

Our report is disseminated primarily electronically, and, in some cases, in printed form. Electronic reports are simultaneously available to all recipients in any form. Copyright 2016-2017 JGR Capital Partners, LLC. No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of JGR Capital Partners, LLC.